BTIG raised the firm’s price target on Insulet (PODD) to $310 from $300 and keeps a Buy rating on the shares after its Q4 earnings beat. The ...

BTIG analyst Marie Thibault raised the firm’s price target on iRhythm (IRTC) to $135 from $120 and keeps a Buy rating on the shares after its ...

Digital Services Analyst Fuller holds a meeting with management in Boston on February 24 hosted by BTIG. Published first on TheFly – the ultimate ...

Wall Street is gearing up for another wave of blank check companies from seasoned and first-time sponsors, showing the ...

Investing.com -- BTIG upgraded Snowflake Inc (NYSE:SNOW) to "Buy" from "Neutral" and introduced a $220 price target on improving demand trends and potential AI-driven growth. The brokerage noted ...

When we spoke three years ago, your research was focused on the shopping center, net lease and health care subsectors. Is there anything new or different about your coverage universe here in 2025? Mr.

For more information about the conference, email [email protected]. Please note that participants must be pre-registered to attend. To access BTIG insights, contact a BTIG representative ...

As of December 23, 2024, the average one-year price target for ImmunityBio is $14.54/share. The forecasts range from a low of $4.80 to a high of $31.50. The average price target represents an ...

Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial Officer Andrea James will attend BTIG’s MedTech, ...

BTIG upgraded Snowflake Inc (NYSE:SNOW) to "Buy" from "Neutral" and introduced a $220 price target on improving demand trends and potential AI-driven growth.